Blinding Integrity in Psychedelic Randomized Clinical Trials

JAMA Psychiatry · Published 2026-04-15 · DOI 10.1001/jamapsychiatry.2026.0255

Authors being retrieved — see the publisher record. https://doi.org/10.1001/jamapsychiatry.2026.0255

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2026

Related articles

Blinding Integrity and Psychedelic Drug Trials—Reply · JAMA Psychiatry · 2026 · Cites or is cited by this article · Same journal
Optimizing Study Design for Clinically Useful Peripheral Molecular Biomarker Discovery in Psychiatry · JAMA Psychiatry · 2026 · Same journal
Error in Table · JAMA Psychiatry · 2026 · Same journal
Medication and Procedural Abortion and Risk of Psychotropic Medication Use · JAMA Psychiatry · 2026 · Same journal
Assessing Drug Efficacy After Multiple Negative Trials—Gepirone’s Journey Through the FDA · JAMA Psychiatry · 2026 · Same journal
Electroencephalography Microstates—A Biomarker for Psychosis? · JAMA Psychiatry · 2026 · Same journal
Deconstructing Social Functioning in Psychosis Risk—From Prediction to Recovery · JAMA Psychiatry · 2026 · Same journal
Confounding and Circularity in Actigraphy Prediction · JAMA Psychiatry · 2026 · Same journal
Psychedelics Trials and Outcomes—A Closer Look—Reply · JAMA Psychiatry · 2026 · Same journal
JAMA Psychiatry · JAMA Psychiatry · 2026 · Same journal